Loading...
XNAS
HOTH
Market cap10mUSD
Jul 09, Last price  
0.91USD
1D
13.41%
1Q
76.46%
IPO
-99.48%
Name

Hoth Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:HOTH chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
94.62%
Rev. gr., 5y
%
Revenues
0k
Net income
-12m
L+52.28%
-2,015,480-2,495,525-7,694,275-7,197,816-14,313,705-11,371,953-7,845,390-8,188,300-12,469,302
CFO
-10m
L+40.49%
-465,243-2,102,626-4,947,215-6,133,198-12,090,129-9,297,854-8,447,094-6,978,251-9,803,918

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
IPO date
Feb 15, 2019
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT